Operating through 125 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (“TMS”), an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 500,000 TMS treatments to over 14,000 patients struggling with depression.
November 11, 2020 – Toronto, ON –
GREENBROOK TMS REPORTS THIRD QUARTER FINANCIAL RESULTS
November 05, 2020 – Toronto, ON –
GREENBROOK TMS ANNOUNCES SUBMISSION OF ITS APPLICATION TO LIST ON NASDAQ
October 20, 2020 – Toronto, ON –
GREENBROOK TMS ANNOUNCES DATES FOR ITS THIRD QUARTER 2020 FINANCIAL RESULTS